{"id":244,"date":"2020-05-28T08:31:38","date_gmt":"2020-05-28T08:31:38","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=244"},"modified":"2020-05-28T08:31:38","modified_gmt":"2020-05-28T08:31:38","slug":"27-may-2020-remdesivir-no-significant-difference-between-a-5-day-and-a-10-day-course","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/27-may-2020-remdesivir-no-significant-difference-between-a-5-day-and-a-10-day-course\/","title":{"rendered":"(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"m-article-header__title f-h18\"><span class=\"title_default\">Remdesivir for 5 or 10 Days in Patients with Severe Covid-19<\/span><\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2015301?query=featured_home<\/p>\n<p class=\"\">In a randomized, open-label, phase 3 trial (<a class=\"ext-link\" href=\"http:\/\/clinicaltrials.gov\/show\/NCT04292899\" target=\"_blank\" rel=\"noopener noreferrer\">NCT04292899<\/a>)involving hospitalized patients with confirmed SARS-CoV-2 infection. In total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group.&nbsp; By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P=0.14).&nbsp;In patients with severe Covid-19 not requiring mechanical ventilation, the trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2015301?query=featured_home In a randomized, open-label, phase 3 trial (NCT04292899)involving hospitalized patients with confirmed SARS-CoV-2 infection. In total, 397 patients underwent randomization and began treatment (200 patients for 5 days&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/27-may-2020-remdesivir-no-significant-difference-between-a-5-day-and-a-10-day-course\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,5,1],"tags":[25],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/244"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=244"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/244\/revisions"}],"predecessor-version":[{"id":246,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/244\/revisions\/246"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}